Eli Lilly announced plans to significantly increase the prices of its weight-loss drug Mounjaro in the UK and other European markets, in an effort to reduce costs in the United States. The price hike in the UK represents a 170% increase for private purchasers, while NHS prices remain unchanged. This adjustment aligns with US government pressures for fair global cost-sharing of pharmaceutical innovation under recent policy initiatives. The move responds to longstanding disparities in drug pricing between the US and Europe.